Overview

Immunservice GmbH is a biopharmaceutical company focusing on the development and commercialization of innovative biomimetic treatments for cancer and infectious diseases. The EMEA has granted Immunservice GmbH SME Status, which provides significant advantages in drug development (cost savings, special advice etc).

The Immunservice GmbH portfolio includes:

• Favorable regulatory statements (including an Orphan Designation in Europe)
• First class know how in biomimetic therapies
• Preclinical and clinical scientific data
• Strong exclusive international patent rights for its core therapies, in particular aerosol cytokine (immune hormone) application.
• Further drug candidates that are in clinical and preclinical development.